Britain and America have finalized a significant trade agreement that will guarantee no duties on UK drug products entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase spending on pharmaceuticals through the public health system. This commitment ensures that tariffs on these vital goods will remain at zero for a timeframe of the next three years.
This agreement comes after previous warnings to significantly raise import taxes on branded drug products, with figures mentioned as high as 100%.
"This agreement between the United Kingdom bolsters the worldwide climate for new treatments and brings much-needed balance to American-British medicine commerce," a release said.
Economic Impact
Drugs are one of the Britain's biggest goods shipped to the United States, which is easily the primary market for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of the third quarter, the UK sold pharmaceutical products totaling billions to the US. This value accounted for 17.4% of total UK exports in that span.
"This guarantee secures employment, stimulates funding and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary stated.
Specific British Pledges
The deal entails several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to raise total public funding on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Last year, rebates were more than twenty percent.
Broader Context
This agreement takes place against a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
This friction were exacerbated by assertions that American consumers were charged significantly more for the same drugs than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while major funding commitments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the last ten years.
